Sexual Health & ED Medications

Sildenafil / Tadalafil / Vardenafil / Apomorphine RDT

A compounded rapid-dissolve ED combination with four active ingredients.

Evidence brief in review

lennoxEDProduct image pending

Common goals: Potential support for erectile response through PDE5 and central dopamine pathways.
Best program fit: May be considered only within clinician-led sexual-health care with cardiovascular, nitrate, interaction, and duplicate-therapy screening.
Format: Rapid-dissolve tablet · 6, 12, or 18 count

Partner education guide

Where this may fit in an offering.

Potential support for erectile response through PDE5 and central dopamine pathways. A rapid-dissolve format may be convenient for selected individuals. May fit clinician-led sexual-health care after safer single-agent options and underlying causes are reviewed.

Educational business-planning summary. Potential benefits vary, are not guaranteed, and require individual-specific clinical review.

01 / Common goals

What people may want to understand.

Primary goals

Potential benefits and goals

Potential support for erectile response through PDE5 and central dopamine pathways.
A rapid-dissolve format may be convenient for selected individuals.
Package quantities of 6, 12, and 18 preserve ordering flexibility.

Program value

How it may support a program

May fit clinician-led sexual-health care after safer single-agent options and underlying causes are reviewed.
Creates an opportunity for cardiovascular, medication, relationship, and hormone screening.

Ingredient-level ED evidence does not establish the safety or added benefit of this four-drug compounded RDT. Additive low-blood-pressure and interaction risks require careful review.

02 / Program fit

Program and operational considerations.

01Administration format: Catalog format: Rapid-dissolve tablet · 6, 12, or 18 count. The prescribing clinician and dispensing pharmacy confirm the exact preparation, concentration, handling, and administration technique.
02Typical frequency: The screenshots show package quantities of 6, 12, and 18—not a dosing schedule. Use only at the clinician-prescribed interval and never infer frequency from package count.
03Expected duration: Use is generally reassessed based on erectile response, tolerability, cardiovascular safety, and whether underlying causes are being addressed.
04Practical considerations: May fit clinician-led sexual-health care after safer single-agent options and underlying causes are reviewed.

03 / Suitability considerations

Who may be considered.

Who may be considered

A carefully screened adult whose goals align with the potential benefits above and who understands that individual response varies.
An individual willing to complete clinician-directed baseline review, monitoring, and an outcome-based follow-up plan.

Qualification notes

May fit clinician-led sexual-health care after safer single-agent options and underlying causes are reviewed.
Strongest fit occurs when the exact formulation, route, source, contraindications, and measurable goals can be clearly documented.

04 / Safety & suitability

What must be screened before treatment.

Common or temporary

Headache, flushing, nasal congestion, indigestion, dizziness, nausea, and visual color change may occur; tadalafil can also cause back pain or muscle aches.
Apomorphine can add nausea, vomiting, dizziness, sweating, sleepiness, or fainting. Combining active agents may intensify tolerability problems.

Serious or important

Severe low blood pressure, chest pain, priapism lasting more than four hours, sudden vision loss, sudden hearing loss, severe allergic reaction, or syncope requires urgent assessment.
Multiple PDE5 inhibitors have overlapping vasodilatory effects. Product labeling states that combination with other ED therapies has not been adequately studied.

Avoid or use only with specialist input

Any nitrate or nitric-oxide donor use, riociguat use, or sexual activity that is medically inadvisable because of cardiovascular status.
Unstable cardiovascular disease, recent major cardiac or neurologic event, severe hypotension, congenital long-QT syndrome or class IA/III antiarrhythmic use when vardenafil is present, or an unverified formula.

Screening checklist

Review cardiovascular fitness for sexual activity, blood pressure, nitrate and riociguat exposure, alpha-blockers, antihypertensives, CYP3A4 interactions, QT-risk medicines, kidney and liver status, eye or hearing history, and prior priapism.
Confirm every active strength, the maximum allowed use, package count, alcohol and recreational-drug use, and whether a simpler single-agent option is safer.

When to refer

Urgent care is appropriate for chest pain, fainting, severe hypotension, sudden vision or hearing change, or an erection lasting more than four hours.
Complex cardiovascular disease, unexplained ED, suspected endocrine disease, penile deformity, significant relationship or mental-health factors, or repeated treatment failure may require specialist evaluation.

Safety information is not exhaustive. Prescribing, screening, dosing, monitoring, and emergency guidance must come from an appropriately licensed clinician and the exact product information.

What the research says · reviewed August 2026

Research and source context.

Each active has a separate evidence story, but combining three PDE5 inhibitors with apomorphine is not established as safer or more effective.

01 / Human research

The clearest clinical signal

Sildenafil, tadalafil, and vardenafil each have approved ED uses in separate products. Sublingual apomorphine was studied in older trials, but the four-drug RDT has not been validated.

02 / Real-world reports

What people describe

People may value a rapid-dissolve format and package-count flexibility, but should understand that quantity is not frequency and that multiple agents can increase adverse effects.

Public personal accounts are unverified and cannot show how common an outcome is.

03 / Cautions

What deserves attention

Nitrates and riociguat are contraindicated, cardiovascular fitness matters, and additive hypotension, priapism, visual or hearing events, syncope, and QT risk require screening.

Does the research match this exact product?

No. Separate ingredient labels and trials do not establish this exact compounded RDT.

Research and regulatory context

Each PDE5 inhibitor has separate ED evidence and labeling, while sublingual apomorphine was studied in older trials. Those data do not show that using three PDE5 inhibitors together with apomorphine is safer or more effective than a selected single agent.

Complete evidence briefClinical summary, safety notes, reported timing, regulatory context, and linked sources in one document.

Evidence brief in reviewReviewed sources are listed above

Evidence and regulatory status can change. Confirm the current label, formulation, route, dose, pharmacy source, jurisdiction, and intended use before offering treatment.

Education before offering.

Treatment information is for education only. It is not medical advice. A licensed clinician will review your health and decide whether a treatment is appropriate for you. Eligibility and availability may vary.

Back to all treatments